Sanofi’s tau-focused Alzheimer’s deal highlights growing confidence in non-amyloid targets
Sanofi’s $1 billion Alzheimer’s deal with ADEL highlights why tau biology is back in focus and what risks still stand between promise and proof.
Pharma & Biotech
Pharma & Biotech
LifeNet Health acquires Tissue Testing Technologies to scale biopreservation in regenerative medicine
LifeNet Health has announced the acquisition of Tissue Testing Technologies LLC (T3), a South Carolina–based biotechnology company specializing in advanced biopreservation. The deal expands LifeNet Health’s capabilities in organ and tissue preservation by integrating proprietary vitrification and warming technologies developed by Tissue Testing Technologies. The transaction is positioned to enhance clinical transplantation success rates, support
Pharma & Biotech
Immunome’s Phase 3 varegacestat data could redefine gamma secretase inhibition in desmoid tumors
Immunome is set to release pivotal Phase 3 varegacestat data in desmoid tumors. Find out what the RINGSIDE results could change for the field.
Pharma & Biotech
Milestone Pharmaceuticals’ CARDAMYST nasal spray wins FDA approval: A new chapter for self-administered PSVT treatment
Milestone Pharmaceuticals’ CARDAMYST FDA approval marks a new era in PSVT care. Find out how this first‑in‑class nasal treatment could transform acute arrhythmia management.
Pharma & Biotech
Vaxxas earns GMP licence for HD-MAP production—what this unlocks for clinical trials
Vaxxas Pty Ltd, the Australian biotechnology company known for its high-density microarray patch (HD-MAP) platform, has secured a manufacturing licence from the Therapeutic Goods Administration (TGA) to produce its investigational vaccine delivery system under Good Manufacturing Practice (GMP) conditions. The licence, granted for its Brisbane-based biomedical facility, clears a critical regulatory hurdle and allows Vaxxas
Pharma & Biotech
Can nivolumab plus AVD become the new frontline treatment in classical Hodgkin lymphoma?
FDA fast-tracks review of Opdivo plus AVD for first-line Hodgkin lymphoma. Find out what this immunotherapy combo could change for patients and providers.
Pharma & Biotech
Is Avenzo’s AVZO-021 the next big player in HR+/HER2- metastatic breast cancer?
Avenzo shares Phase 1 data on CDK2 inhibitor AVZO-021 in HR+/HER2- breast cancer. Find out what it means for post-CDK4/6 resistance strategies in 2025.
Pharma & Biotech
Can Novo Nordisk’s semaglutide 7.2 mg set a new standard in obesity treatment?
Novo Nordisk's semaglutide 7.2 mg achieves 20.7% weight loss. Find out what this EU regulatory step means for obesity treatment and patient outcomes in 2026.
Pharma & Biotech
Ivonescimab delivers 80% response in TNBC: Is Akeso redefining PD-1 treatment?
Ivonescimab shows 80 percent response in TNBC Phase II study. Explore how Akeso’s bispecific strategy could reshape PD-1 therapy in first-line settings.
Pharma & Biotech
Sobi bets $950m on Arthrosi to reshape chronic gout treatment with pozdeutinurad
Swedish Orphan Biovitrum AB (Sobi) has entered into a definitive agreement to acquire Arthrosi Therapeutics Inc. for $950 million upfront and up to $550 million in milestone payments. The deal brings the investigational gout drug pozdeutinurad (AR882) into Sobi’s pipeline, positioning the oral URAT1 inhibitor as a potential anchor asset in a late-stage inflammatory franchise.